Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels

Verónica Bravo Villa MD | Job Romero MD | Eunice Rojas-Zaldivar MD | Martha Cervantes BS | María del Rosario Villa-Márquez BS | Patricia Baz MD | Gabriela Cesarman-Maus MD, PhD

1Hematology Department, Instituto Nacional de Cancerología, México City, CDMX, México
2Clinical Laboratory, Instituto Nacional de Cancerología, México City, CDMX, México
3Laboratorio Privado de Genética, México City, México

Correspondence
Gabriela Cesarman-Maus, Av. San Fernando # 22, Colonia Sección XVI, Tlalpan, Cuidad de México, México. Email: gcesarman@gmail.com

Handling Editor: Dr Suzanne Cannegieter.

Abstract
Introduction: Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and probably more effective than dalteparin for the treatment of cancer-associated thrombosis (CAT) as reported in the ADAM-VTE and Caravaggio studies, which included a low percentage of underweight patients. Lower-weight–based dosing is supported by cancer-specific studies such as half-dose edoxaban in the Hokusai-VTE cancer trial in individuals weighing <60 kg.

Objective: To examine apixaban plasma trough levels in low-weight individuals with CAT, stably anticoagulated with full or half-dose apixaban.

Methods: This was a cross-sectional study of 61 routinely treated patients with active cancer and venous thromboembolism comparing three groups: patients weighing >60 kg treated with apixaban 5 mg twice daily, patients weighing ≤60 kg also receiving apixaban 5 mg twice daily, and patients weighing ≤60 kg given half-dose apixaban (2.5 mg twice daily). Apixaban plasma steady-state trough levels were determined on a single occasion.

Results: Mean apixaban plasma trough levels were similar for patients weighing >60 kg on full-dose apixaban to those weighing ≤60 kg taking 2.5 mg twice daily (mean, 109 ng/dL; 95% confidence interval [CI], 74-145; standard deviation [SD]: 77.6; and mean,101 ng/dL, 95% CI, 67-135; SD: 80, respectively). Mean values for low-weight patients (≤60 kg) on the full 5 mg twice-daily dosing tended to be higher (mean, 136 ng/dL; 95% CI, 70-201; SD:114), without statistical significance (P = .22).

Conclusions: This study supports the rationale for studying weight-based adjustments in apixaban dosing in prospective studies evaluating safety and efficacy of dose reduction in low-weight patients with cancer.

KEYWORDS
anticoagulants, apixaban, body weight, cancer, plasma levels, venous thromboembolism
Apixaban has been shown to be an effective and relatively safe treatment for patients with cancer-associated thrombosis (CAT), yet low-weight patients are underrepresented in cancer-specific prospective studies. Only close to 1 in 10 patients included in apixaban CAT trials weigh <60 kg. Large studies using apixaban for the treatment of venous thrombosis conclude that additional information is needed regarding the efficacy and safety of apixaban in patients with cancer and low body weight. In the AMPLIFY-EXT trial, a non–cancer-specific study examining the use of apixaban for extended treatment venous thromboembolic events (VTEs), the mean weight was 80 kg, with only 7% of patients weighing <60 kg. Notably, in these latter patients, there was no increased risk of bleeding with the use of 5 mg twice-daily dosing, nor was there a decreased benefit with 2.5 mg twice daily. A concern in people with cancer is the higher rate of bleeding when using anticoagulants, as compared to people without cancer; therefore in an attempt to decrease bleeding risk, dose adjustments according to weight have been used in clinical studies such as half-dose edoxaban for patients weighing <60 kg in the Hokusai-VTE cancer trial. Weight-adjusted rivaroxaban in children and adolescents has been shown to result in similar exposures to those of adults receiving full-dose anticoagulation, supporting the concept that research into weight adjustment of apixaban dosing is reasonable.

We sought to determine whether low-weight individuals (≤60 kg) receiving full- or half-dose apixaban have similar plasma trough levels to patients >60 kg treated with standard-dose apixaban.

We performed a cross-sectional study of 61 stably anticoagulated patients with active cancer and confirmed venous thromboembolism. Per standard procedure at our institution, patients with CAT weighing between 61 and 120 kg initially receive 10 mg twice daily of apixaban for 7 days, or, alternatively, patients complete at least 5 days of therapeutic enoxaparin if they have already been started on low-molecular-weight heparin in the emergency room; subsequently, patients receive apixaban 5 mg twice daily. Individuals weighing ≤60 kg also receive 7 days of apixaban 10 mg twice daily or full-dose enoxaparin followed by apixaban 5 mg twice daily for the first month. Thereafter, the dose is dropped to 2.5 mg twice daily. Creatinine clearance results (estimated by the Cockcroft-Gault equation) reported in the electronic patient chart within 1 month from the development of a VTE were documented. Patient consent was obtained for an additional blood sample for measurement of apixaban plasma trough levels after a minimum of 7 days on steady-dose anticoagulation. Apixaban plasma levels in patients on 2.5 mg twice daily were also taken after a minimum of 7 days of anticoagulation at this dose. The sample was drawn before the morning dose during routine laboratory workup. Blood was drawn 10 to 12 hours after the prior dose of apixaban into sodium citrate (3.2%) tubes, and plasma was stored frozen at −70°C. A validated STA-Liquid Anti-Xa assay kit with a STA-apixaban calibrator (STA Compact Max; Diagnostica Stago, Parsippany, NJ, USA) was used. Approval by the Institute’s Research Committee in accordance with the Declaration of Helsinki was obtained (No. 2020/0083).

Categorical variables are presented as frequencies and percentages. Student’s t test was used to test whether weight or apixaban dose impact apixaban levels. Analysis of variance was used to determine mean values and confidence intervals for each group of patients. Data were analyzed using SPSS software for Windows, version 23 (IBM Corp., Armonk, NY, USA). A P value < .05 was considered statistically significant.

Of all patients treated in the Thrombosis Unit at the Instituto Nacional de Cancerología throughout 2018-2019, 40% weighed ≤60 kg, and 25.4% weighed <55 kg. We included 61 patients with active cancer, as defined by the ISTH, who were undergoing routine anticoagulant treatment for venous thrombosis. Twenty-one patients weighed >60 kg and were receiving full-dose anticoagulation (5 mg twice daily), 15 patients weighed ≤60 kg and were receiving the same full-dose treatment as part of their first month of routine anticoagulation. A third group of 25 patients who weighed ≤60 kg were receiving half-dose apixaban (2.5 mg twice daily). Patients’ characteristics and laboratory measurements are summarized in

1 | INTRODUCTION

The cross-sectional study of apixaban plasma trough levels in patients with cancer.

Patients under 60 kg on half-dose apixaban attained levels similar to those over 60 kg on full dose.

Creatinine clearances were all above 30 mL/min and did not correlate with apixaban trough levels.

Findings support a rationale for research into weight-adjusted dosing for patients with cancer.
Table 1. None of the baseline characteristics other than weight were significantly different between groups.

Apixaban plasma trough levels in patients weighing >60 kg on full 5 mg twice-daily dosing were used as reference (mean, 109 ng/dL; 95% confidence interval [CI], 74-145; standard deviation [SD], 77.6). These levels overlapped with those of patients weighing ≤60 kg and taking half-dose apixaban (mean, 101 ng/dL, 95% CI, 67-135; SD, 80), while patients weighing ≤60 kg taking 5 mg twice daily did show a tendency toward higher mean apixaban plasma levels (mean, 136 ng/dL; 95% CI, 70.-201; SD, 113.6), which was not statistically significant, as seen by cluster analysis (Figure 1). When we studied patients weighing <50 kg receiving half-dose apixaban, plasma trough levels were found to be similar to those of patients weighing >60 kg receiving full-dose apixaban (P =.32) Creatinine clearance in all of our patients was >30 ml/min and did not correlate with apixaban plasma trough levels (linear $R^2 = 5.332E-4$; P =.71; Figure 2).
We examined the association of lower weight with apixaban levels in cancer patients with venous thrombosis at our institution. Of all patients treated throughout 2018-2019, a high proportion weighed ≤60 kg (40%) and one-fourth weighed <55 kg. This represents a much higher proportion of patients with low weight when compared to published cancer-specific studies in which only close to 10% of patients weigh <60 kg.\(^1\) - \(^3\), \(^4\) When comparing apixaban plasma trough levels in individuals weighing >60 kg to those weighing ≤60 kg on full-dose anticoagulation, low-weight individuals had a tendency toward higher mean apixaban plasma levels, though this was not statistically significant. This could be due to the small number of patients. Individuals weighing ≤60 kg and receiving half-dose apixaban had similar apixaban plasma trough levels to patients weighing >60 kg on full anticoagulation. These findings suggest that underweight individuals may be adequately anticoagulated with lower-dose apixaban.

To our knowledge, studies of apixaban plasma levels in low-weight individuals with active cancer have not been published. Of note, mean apixaban trough levels in our study were higher than those previously reported by others for patients without cancer (Table 2).\(^9\) - \(^11\) The underlying reason for this finding is probably multifactorial. Factors that may bear on apixaban levels include drug interactions, as well as poor oral intake or inadequate absorption.\(^12\) Ethnic origin may also be relevant to apixaban plasma levels. Reports of Asian population pharmacokinetic analyses in individuals with nonvalvular atrial fibrillation or venous thromboembolism showed a 13.5% to 20.2% increase in apixaban area under the plasma concentration-time curve levels when compared to the White population.\(^13\) - \(^15\) There is little information on pharmacodynamics of apixaban in the Latin American population, which is known to have significant Asian ancestry.\(^16\) In cancer-specific anticoagulation trials such as ADAM-VTE, only 0.4% were of Latin descent.\(^1\) Renal function did not correlate with apixaban plasma trough levels (linear \(R^2 = 5.332E-4; P = .71\)), likely due to creatinine clearances above 30 mL/min in all of our patients (Figure 2).

The main limitations of our study are the small number of patients tested and the lack of information of confounding factors such as concomitant medication. In addition, patients who received apixaban 2.5 mg twice daily also survived their CAT, and lived long enough to receive this dose. This may have led to survival bias (ie, the best patients received 2.5 mg twice daily and may have different

---

### TABLE 2  Previously reported apixaban plasma levels under steady state exposure in patients without cancer

| Patient characteristics and weight range | Trough levels 2.5 mg BID (ng/ml) | Trough levels 5 mg BID (ng/ml) | References |
|------------------------------------------|----------------------------------|--------------------------------|------------|
| Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTE) >60 kg\(^a\) | 32 (11-90) | 63 (22-77) | Package insert: Eliquis (apixaban): Bristol-Meyers Squibb Company. Princeton, NJ (11) |
| Atrial fibrilation Weight range 50-103 kg | 48 (SD: 16-75) \(N = 10\) | 77 (SD: 31-178) \(N = 60\) | Skepphoi M et al. (12) |
| Healthy volunteers Weight range 58.6-104.4 kg | 21 (17% CV) | 49.6 (20% CV) | Frost el al. (13) |

Abbreviations: CV, coefficient of variation; DVT, Deep venous thrombosis; PE, Pulmonary embolism; SD, Standard deviation; VTE, venous thromboembolic event.

\(^a\) No weight range is reported.

---

### FIGURE 2  Correlation between apixaban trough plasma levels and serum creatinine levels
apixaban levels than patients who were very ill and never received the 2.5-mg dosage), though not to a change in apixaban levels. Notably, the safety and efficacy of using half-dose apixaban requires prospective evaluation of these outcomes, which were not measured in this cross-sectional study.

4 | CONCLUSIONS

Weight-adjusted apixaban in patients weighing ≤60 kg results in drug concentrations similar to those attained with full-dose treatment in patients weighing >60 kg. These findings support the rationale for studying weight-adjusted apixaban doses with prospective assessment of bleeding and rethrombosis.

ACKNOWLEDGMENTS

None.

RELATIONSHIP DISCLOSURE

None.

AUTHOR CONTRIBUTIONS

VB: data collection and article writing; JR: writing, laboratory work, and data collection; MC: laboratory work; ER: statistic work; MRVM: data collection and laboratory work; PB: data collection; and GC-M, research planning and article writing.

ORCID

Verónica Bravo Villa https://orcid.org/0000-0002-7937-7403
Gabriela Cesarman-Maus https://orcid.org/0000-0002-8397-0330

REFERENCES

1. McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18(2):411-421.
2. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599-1607.
3. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
4. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708.
5. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 2019;3(22):3770-9.
6. Raskob GE, Bülter HR, Segers A. Edoxaban for cancer-associated venous thromboembolism. N Engl J Med. 2018;379(1):95-96.
7. Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019;6(10):e500-e509.
8. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891-1894.
9. Package insert: Eliquis (apixaban): Bristol-Meyers Squibb Company. Princeton, NJ.
10. Skeppholm M, Al-Aieshy F, Berndtsson M, et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res. 2015;136(1):148-153.
11. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776-786.
12. Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58(10):1265-1279.
13. Frost C, Shenker A, Jhee S, et al. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. Clin Pharmacol. 2018;10:153-163.
14. Yamahira N, Frost C, Fukase H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther. 2014;52(7):564-573.
15. Cui Y, Song Y, Wang J, et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol. 2013;5:177-184.
16. Skoglund P, Reich D. A genomic view of the peopling of the Americas. Curr Opin Genet Dev. 2016;41:27-35.

How to cite this article: Bravo Villa V, Romero J, Rojas-Zaldívar E, et al. Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels. Res Pract Thromb Haemost. 2021;5:421-425. https://doi.org/10.1002/rth2.12492